A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

Exclusion Criteria

• •Have any type of diabetes with hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater.
• •Have significant history of or currently have Major Depressive Disorder or psychiatric disorder within the last 2 years.
• •Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome.
• •Have known clinically significant gastric emptying abnormality.
• •Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass)
• •Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer.
• •Have an abnormal 12-lead electrocardiogram (ECG) at screening.
• •Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drug.
• •Participants must not be currently participating in or completed a clinical trial within the last 90 days.
• •Have a known allergy or hypersensitivity to midazolam, simvastatin, rosuvastatin, or digoxin.